Details for New Drug Application (NDA): 075128
✉ Email this page to a colleague
NDA 075128 describes AFEDITAB CR, which is a drug marketed by Watson Labs and Watson Labs Teva and is included in two NDAs. Additional details are available on the AFEDITAB CR profile page.
The generic ingredient in AFEDITAB CR is nifedipine. There are thirty-nine drug master file entries for this compound. Thirty-six suppliers are listed for this compound. Additional details are available on the nifedipine profile page.
The generic ingredient in AFEDITAB CR is nifedipine. There are thirty-nine drug master file entries for this compound. Thirty-six suppliers are listed for this compound. Additional details are available on the nifedipine profile page.
Summary for 075128
| Tradename: | AFEDITAB CR |
| Applicant: | Watson Labs Teva |
| Ingredient: | nifedipine |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 075128
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET, EXTENDED RELEASE;ORAL | Strength | 30MG | ||||
| Approval Date: | Mar 10, 2000 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
